Therefore, it is highly possible that a TM4SF5-specific peptide vaccine and an anti-TM4SF5 monoclonal antibody can be valuable agents in clinical management of HCC and colon cancer metastases. This evidence concerns the gene TM4SF5 and hepatocellular carcinoma.